These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 2965135

  • 1. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results.
    Van Laethem Y, Hermans P, De Wit S, Goosens H, Clumeck N.
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():81-7. PubMed ID: 2965135
    [Abstract] [Full Text] [Related]

  • 2. Teicoplanin in infections caused by methicillin-resistant staphylococci.
    Drabu YJ, Walsh B, Blakemore PH, Mehtar S.
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():89-92. PubMed ID: 2965136
    [Abstract] [Full Text] [Related]

  • 3. Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: teicoplanin versus vancomycin in a retrospective study.
    Huang JH, Hsu RB.
    Scand J Infect Dis; 2008 Jan; 40(6-7):462-7. PubMed ID: 18584532
    [Abstract] [Full Text] [Related]

  • 4. Activity of teicoplanin in localized experimental infections in rats.
    Arioli V, Berti M, Candiani G.
    J Hosp Infect; 1986 Mar; 7 Suppl A():91-9. PubMed ID: 2871103
    [Abstract] [Full Text] [Related]

  • 5. Teicoplanin, vancomycin, rifampicin: in-vivo and in-vitro studies with Staphylococcus aureus.
    Carper HT, Sullivan GW, Mandell GL.
    J Antimicrob Chemother; 1987 May; 19(5):659-62. PubMed ID: 2956229
    [Abstract] [Full Text] [Related]

  • 6. Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.
    Asseray N, Jacqueline C, Le Mabecque V, Batard E, Bugnon D, Potel G, Caillon J.
    Antimicrob Agents Chemother; 2005 Feb; 49(2):857-9. PubMed ID: 15673789
    [Abstract] [Full Text] [Related]

  • 7. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus.
    Chambers HF, Sande MA.
    Antimicrob Agents Chemother; 1984 Jul; 26(1):61-4. PubMed ID: 6236747
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin.
    Brunet F, Vedel G, Dreyfus F, Vaxelaire JF, Giraud T, Schremmer B, Monsallier JF.
    Eur J Clin Microbiol Infect Dis; 1990 Feb; 9(2):145-7. PubMed ID: 2138543
    [Abstract] [Full Text] [Related]

  • 10. Comparison of teicoplanin and vancomycin in vitro activity on clinical isolates of Staphylococcus aureus.
    Tascini C, Flammini S, Leonildi A, Ciullo I, Tagliaferri E, Menichetti F.
    J Chemother; 2012 Aug; 24(4):187-90. PubMed ID: 23040680
    [Abstract] [Full Text] [Related]

  • 11. Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration.
    Peeters O, Ferry T, Ader F, Boibieux A, Braun E, Bouaziz A, Karsenty J, Forestier E, Laurent F, Lustig S, Chidiac C, Valour F, Lyon BJI study group.
    BMC Infect Dis; 2016 Nov 03; 16(1):622. PubMed ID: 27809799
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Teicoplanin in the treatment of infections by staphylococci, Clostridium difficile and other gram-positive bacteria.
    de Lalla F, Santoro D, Rinaldi E, Suter F, Cruciani M, Guaglianone MH, Rizzardini G, Pellegata G.
    J Antimicrob Chemother; 1989 Jan 03; 23(1):131-42. PubMed ID: 2526109
    [Abstract] [Full Text] [Related]

  • 14. Vancomycin versus teicoplanin in the therapy of experimental methicillin-resistant Staphylococcus aureus (MRSA) meningitis.
    Sipahi OR, Arda B, Yurtseven T, Sipahi H, Ozgiray E, Suntur BM, Ulusoy S.
    Int J Antimicrob Agents; 2005 Nov 03; 26(5):412-5. PubMed ID: 16221540
    [Abstract] [Full Text] [Related]

  • 15. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts.
    Van der Auwera P, Aoun M, Meunier F.
    Antimicrob Agents Chemother; 1991 Mar 03; 35(3):451-7. PubMed ID: 1828134
    [Abstract] [Full Text] [Related]

  • 16. Activity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy.
    Tarasi A, Cassone M, Monaco M, Tarasi D, Pompeo ME, Venditti M.
    J Chemother; 2003 Jun 03; 15(3):239-43. PubMed ID: 12868549
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Shen WC, Chiang YC, Chen HY, Chen TH, Yu FL, Tang CH, Sue YM.
    Nephrology (Carlton); 2011 Nov 03; 16(8):697-703. PubMed ID: 21707841
    [Abstract] [Full Text] [Related]

  • 19. [The comparative costs of vancomycin treatment versus teicoplanin in osteoarticular infection caused by methicillin-resistant staphylococci].
    Pham Dang C, Gouin F, Touchais S, Richard C, Potel G.
    Pathol Biol (Paris); 2001 Sep 03; 49(7):587-96. PubMed ID: 11642024
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.